AR089248A1 - Composiciones que contienen inhibidores de quinasas - Google Patents

Composiciones que contienen inhibidores de quinasas

Info

Publication number
AR089248A1
AR089248A1 ARP120104724A AR089248A1 AR 089248 A1 AR089248 A1 AR 089248A1 AR P120104724 A ARP120104724 A AR P120104724A AR 089248 A1 AR089248 A1 AR 089248A1
Authority
AR
Argentina
Prior art keywords
compositions containing
kinase inhibitors
compositions
containing kinase
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
K Spence Julie
E Padden Brian
Shi Yi
M Lipari John
E Dias Lloyd
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089248(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR089248A1 publication Critical patent/AR089248A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP120104724 2011-12-14 2012-12-14 Composiciones que contienen inhibidores de quinasas AR089248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161570679P 2011-12-14 2011-12-14

Publications (1)

Publication Number Publication Date
AR089248A1 true AR089248A1 (es) 2014-08-06

Family

ID=47559656

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104724 AR089248A1 (es) 2011-12-14 2012-12-14 Composiciones que contienen inhibidores de quinasas

Country Status (25)

Country Link
US (1) US20150126545A1 (zh)
EP (1) EP2790726A1 (zh)
JP (1) JP2015500343A (zh)
KR (1) KR20150000869A (zh)
CN (1) CN103987406A (zh)
AR (1) AR089248A1 (zh)
AU (1) AU2012352112A1 (zh)
BR (1) BR112014014342A2 (zh)
CA (1) CA2857337A1 (zh)
CL (1) CL2014001548A1 (zh)
CO (1) CO7010829A2 (zh)
CR (1) CR20140333A (zh)
DO (1) DOP2014000128A (zh)
EC (1) ECSP14008671A (zh)
HK (1) HK1203368A1 (zh)
IL (1) IL232725A0 (zh)
MX (1) MX2014007158A (zh)
PE (1) PE20142103A1 (zh)
PH (1) PH12014501333A1 (zh)
RU (1) RU2014128601A (zh)
SG (1) SG11201402776WA (zh)
TW (1) TW201330850A (zh)
UY (1) UY34518A (zh)
WO (1) WO2013090666A1 (zh)
ZA (1) ZA201404134B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014084A (es) * 2015-05-05 2018-06-20 Psivida Inc Formulaciones de deposito inyectables.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
EP2373662B1 (en) 2008-12-05 2014-09-24 AbbVie Bahamas Ltd. Thieno[3,2-c]pyridine derivatives as kinase inhibitors for use in the treatment of cancer
EP2403342A4 (en) * 2009-03-03 2013-06-05 Alcon Res Ltd PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI)
ES2523999T3 (es) * 2010-06-09 2014-12-03 Abbvie Bahamas Ltd. Dispersiones sólidas que contienen inhibidores de cinasas

Also Published As

Publication number Publication date
BR112014014342A2 (pt) 2017-06-13
SG11201402776WA (en) 2014-06-27
DOP2014000128A (es) 2014-08-15
TW201330850A (zh) 2013-08-01
EP2790726A1 (en) 2014-10-22
HK1203368A1 (zh) 2015-10-30
CN103987406A (zh) 2014-08-13
ZA201404134B (en) 2015-02-25
MX2014007158A (es) 2014-08-29
KR20150000869A (ko) 2015-01-05
CR20140333A (es) 2014-09-29
PE20142103A1 (es) 2015-01-11
UY34518A (es) 2013-07-31
JP2015500343A (ja) 2015-01-05
US20150126545A1 (en) 2015-05-07
ECSP14008671A (es) 2015-11-30
CL2014001548A1 (es) 2014-10-10
AU2012352112A1 (en) 2014-06-12
IL232725A0 (en) 2014-07-31
PH12014501333B1 (en) 2014-09-15
WO2013090666A1 (en) 2013-06-20
CO7010829A2 (es) 2014-07-31
PH12014501333A1 (en) 2014-09-15
CA2857337A1 (en) 2013-06-20
RU2014128601A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
NZ605434A (en) Solid dispersions containing kinase inhibitors
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MY171553A (en) Pyrrolotriazinone derivatives as pi3k inhibitors
BR112012023021A2 (pt) compostos de indazol e seus usos
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
PH12015500813A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2014003025A (es) Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
WO2012145575A3 (en) Therapy for leukemia
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
AR089248A1 (es) Composiciones que contienen inhibidores de quinasas
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
MX2012014348A (es) Formas cristalinas de inhibidores de cinasa.
NZ605436A (en) Crystalline forms of kinase inhibitors
GR1008227B (el) Σταθερο φαρμακευτικο σκευασμα ενος βενζιμιδαζολικου αναστολεα της αντλιας πρωτονιων και μεθοδος για την παρασκευη αυτου
CU20100004A7 (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k

Legal Events

Date Code Title Description
FB Suspension of granting procedure